TALOPH(SH:600222) Xin Lang Cai Jing·2025-11-28 06:27Group 1 - The core viewpoint of the news is that Tai Long Pharmaceutical experienced a stock price increase of 5.37%, reaching 8.04 CNY per share, with a trading volume of 339 million CNY and a turnover rate of 7.58%, resulting in a total market capitalization of 4.614 billion CNY [1] - Tai Long Pharmaceutical, established on August 31, 1998, and listed on November 5, 1999, is located in Zhengzhou, Henan Province, and operates in the pharmaceutical manufacturing industry, focusing on traditional Chinese medicine, proprietary Chinese medicines, chemical drug manufacturing, and pharmaceutical wholesale [1] - The company's main business revenue composition includes 70.59% from drug manufacturing, 14.71% from drug research and development services, 14.42% from pharmaceutical material circulation, and 0.28% from other sources [1] Group 2 - From the perspective of major circulating shareholders, Guangfa Fund holds a position among the top shareholders of Tai Long Pharmaceutical, with Guangfa Pension Index A (000968) reducing its holdings by 264,000 shares in the third quarter, now holding 2.9719 million shares, which is 0.52% of the circulating shares [2] - Guangfa Pension Index A (000968) was established on February 13, 2015, with a latest scale of 1.395 billion CNY, and has achieved a year-to-date return of 7.52%, ranking 3613 out of 4206 in its category [2] - The fund manager, Cao Shiyu, has been in charge for 1 year and 352 days, with a total asset scale of 33.465 billion CNY, achieving the best fund return of 98.5% and the worst return of -2.74% during his tenure [2]